Voices
Arturo LoAIza-Bonilla: St. Luke’s University Health Network established DPD/DPYD testing pathways Before FDA Guidance
Arturo LoAIza-Bonilla

Arturo LoAIza-Bonilla: St. Luke’s University Health Network established DPD/DPYD testing pathways Before FDA Guidance

Arturo LoAIza-Bonilla, Systemwide Chief of Hematology and Oncology at St. Luke’s University Health Network, and Co-Founder and Chief Medical  AI Officer (CMAIO) of Massive Bio, shared a post on LinkedIn:

“At St. Luke’s University Health Network Cancer Center we had proactively recognized the importance of pharmacogenomics in patient outcomes, and established testing pathways for DPD/DPYD assessment for all our patients prior to Capecitabine and Fluorouracil based therapies.

Now the FDA is making it official, and we were ready. Our team is committed to providing timely and reliable treatment to all our patients, and proud on our focus on quality and best practices.”

More posts featuring Arturo LoAIza-Bonilla.

Arturo Loaiza-Bonilla FDA St. Luke's University Health Network